AIM - AIM ImmunoTech's Ampligen trial in COVID-19 'long Haulers' moves forward

AIM ImmunoTech (AIM) gains 13% in premarket after Institutional Review Board's ((IRB)) green signal to commence enrollment in post-COVID-19 "Long Hauler" portion of the active AMP-511 Expanded Access Program, evaluating Ampligen.The program is authorized to enroll up to 100 active trial participants, 20 of whom may be Long Haulers.The company in October announced that the myalgic encephalomyelitis / chronic fatigue syndrome ((ME/CFS)) trial received IRB approval to include patients previously diagnosed with COVID-19, but who now demonstrate post-acute infection chronic fatigue-like symptoms.Ampligen is AIM's TLR3 agonist immune-system modulator. It is approved in Argentina as the world's first therapy for severe Chronic Fatigue Syndrome and the company says it is the only late-stage drug in the U.S. development pipeline for ME/CFS.

For further details see:

AIM ImmunoTech's Ampligen trial in COVID-19 'long Haulers' moves forward